DE69709493T2 - Substituierte Indazolderivate - Google Patents

Substituierte Indazolderivate

Info

Publication number
DE69709493T2
DE69709493T2 DE69709493T DE69709493T DE69709493T2 DE 69709493 T2 DE69709493 T2 DE 69709493T2 DE 69709493 T DE69709493 T DE 69709493T DE 69709493 T DE69709493 T DE 69709493T DE 69709493 T2 DE69709493 T2 DE 69709493T2
Authority
DE
Germany
Prior art keywords
formula
compounds
indazole derivatives
substituted indazole
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69709493T
Other languages
German (de)
English (en)
Other versions
DE69709493D1 (de
Inventor
Anthony Marfat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of DE69709493D1 publication Critical patent/DE69709493D1/de
Publication of DE69709493T2 publication Critical patent/DE69709493T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69709493T 1996-06-27 1997-06-11 Substituierte Indazolderivate Expired - Fee Related DE69709493T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2107296P 1996-06-27 1996-06-27

Publications (2)

Publication Number Publication Date
DE69709493D1 DE69709493D1 (de) 2002-02-14
DE69709493T2 true DE69709493T2 (de) 2002-10-31

Family

ID=21802182

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69709493T Expired - Fee Related DE69709493T2 (de) 1996-06-27 1997-06-11 Substituierte Indazolderivate

Country Status (8)

Country Link
US (1) US5958953A (fr)
EP (1) EP0816357B1 (fr)
JP (1) JP3032840B2 (fr)
AT (1) ATE211740T1 (fr)
CA (1) CA2208792C (fr)
DE (1) DE69709493T2 (fr)
ES (1) ES2168581T3 (fr)
MX (1) MX9704856A (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2223920A3 (fr) * 1996-06-19 2011-09-28 Aventis Pharma Limited Composes azabicycliques substitues
CA2264798A1 (fr) * 1996-09-04 1998-03-12 Pfizer Inc. Derives d'indazole et leur utilisation en tant qu'inhibiteurs de phosphodiesterase (pde) de type iv et de la production du facteur de necrose des tumeurs (tnf)
SK6262000A3 (en) * 1997-11-04 2002-03-05 Pfizer Prod Inc Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
CA2381802C (fr) 1999-08-21 2010-12-07 Byk Gulden Lomberg Chemische Fabrik Gmbh Combinaison synergique de roflumilast et de salmeterol
WO2001079198A1 (fr) 2000-04-18 2001-10-25 Agouron Pharmaceuticals, Inc. Pyrazoles permettant d'inhiber des proteines kinases
WO2003035904A2 (fr) * 2001-10-19 2003-05-01 Centre Hospitalier Regional Et Universitaire De Tours Procedes et compositions pour evaluer la reponse a un traitement a base d'anticorps
US20040126372A1 (en) * 2002-07-19 2004-07-01 Abbott Biotechnology Ltd. Treatment of TNFalpha related disorders
EA200501548A1 (ru) 2003-04-01 2006-02-24 Апплайд Резеч Системз Арс Холдинг Н.В. Ингибиторы фосфодиэстераз при бесплодии
US20070190657A1 (en) * 2004-06-15 2007-08-16 Universite Francois Rabelais Methods of assessing susceptibility to drug-induced thrombocytopenia
JP4912314B2 (ja) * 2004-10-26 2012-04-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 因子Ｘａ化合物
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
NZ591701A (en) 2005-05-16 2012-11-30 Abbott Biotech Ltd Use of tnf inhibitor for treatment of erosive polyarthritis
US20080249202A1 (en) * 2005-09-22 2008-10-09 Huntsman Internationl Llc Method for the Production of Polyisocyanates
WO2008063213A2 (fr) 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Compositions destinées au traitement de la polyarthrite psoriasique et leurs applications
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
EP2171451A4 (fr) 2007-06-11 2011-12-07 Abbott Biotech Ltd Procédés de traitement de l'arthrite idiopathique juvénile
WO2010120854A1 (fr) * 2009-04-15 2010-10-21 Glaxosmithkline Llc Composés chimiques
WO2012026511A1 (fr) * 2010-08-27 2012-03-01 協和発酵キリン株式会社 Composition pharmaceutique

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6034098B2 (ja) * 1981-01-29 1985-08-07 富士写真フイルム株式会社 ハロゲン化銀カラ−感光材料の処理方法
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US5444038A (en) * 1992-03-09 1995-08-22 Zeneca Limited Arylindazoles and their use as herbicides
DE19610882A1 (de) * 1996-03-20 1997-09-25 Dresden Arzneimittel Neue 1,3,5-trisubstituierte Indazol-Derivate mit antiasthmatischer, antiallergischer, entzündungshemmender und immunmodulierender Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Also Published As

Publication number Publication date
ES2168581T3 (es) 2002-06-16
CA2208792C (fr) 2002-12-10
EP0816357B1 (fr) 2002-01-09
US5958953A (en) 1999-09-28
ATE211740T1 (de) 2002-01-15
JPH1072445A (ja) 1998-03-17
JP3032840B2 (ja) 2000-04-17
EP0816357A1 (fr) 1998-01-07
DE69709493D1 (de) 2002-02-14
MX9704856A (es) 1998-06-30
CA2208792A1 (fr) 1997-12-27

Similar Documents

Publication Publication Date Title
DE69709493D1 (de) Substituierte Indazolderivate
YU11299A (sh) Derivati indazola
MY116915A (en) Substituted indazole analogs
MY132499A (en) Substituted indazole derivatives and related compounds
DK1029853T3 (da) Heteroaromatiske bicykliske derivativer, der er egnede som anticancermidler
DK0928788T3 (da) Imidazolidin-4-on-derivater, der er nyttige som anticancer-midler
EA200500814A1 (ru) Производные пирролопиримидина
MY132073A (en) Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
YU69902A (sh) Novi derivati piperazina
DE69830504D1 (de) Antithrombotische mitteln
ATE260255T1 (de) 5-oxo-pyrrolidine-2-carbonsäure- hydroxamidderivate
CA2362394A1 (fr) Derives de quinolin-2-one a substitution heteroaryle convenant comme anti-cancereux
ATE253545T1 (de) Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
AP9701039A0 (en) Derivatives of 2- (2-oxo-ethlidene)-imidazolidin-4-one.
DK0889876T3 (da) Meta-substituerede phenylensulfonamidderivater
MXPA02012034A (es) Derivados de tiofeno utiles como agentes anticancerosos.
DK0894084T3 (da) Kanelsyrederivater og deres anvendelse som integrinantagonister
MXPA02003977A (es) Inhibidores de adhesion de celula mediada por al°2.
FI810604L (fi) Foerfarande foer framstaellning av indanderivat
AP1564A (en) Piperazinyl sulfonic acid derivatives, their pharmaceutical compositions and methods of use.
PT992509E (pt) Novos derivados macrolidos
WO2001010860A3 (fr) Derives de quinazolinone et d'azaquinazolinone
DE60107832D1 (en) Chromenylmethylpyrimidindiamine als antibakterielle wirkstoffe
ATE445589T1 (de) Neue retinoidderivate und eine pharmazeutische anti-krebs-zusammensetzung, die diese verbindungen enthält
DE69908855D1 (de) 9a, 11b-dehydro Derivative von 9-oxime-3-keto-6-0-methylerythromycin

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee